Herein, we consider venous immunothrombotic mechanisms in SARS-CoV-2 infection and
anti-SARS-CoV-2 DNA vaccination. Primary SARS-CoV-2 infection with systemic viral RNA …

Background Anticoagulation is important for extracorporeal membrane oxygenation
(ECMO). Heparin is widely used; however, in some cases, it is not suitable for patients …

Background/Aim: To investigate the efficacy (prognosis, coagulation/inflammation
biomarkers) and safety (bleeding events) of different anticoagulation dosages in COVID-19 …

Background In line with the growing industrial applications of copper oxide nanoparticles
(CuONPs) in various fields, concerns about their potentially harmful consequences on the …

Introduction The literature recommends against the use of fondaparinux in patients with
kidney failure and dialysis as it may, with repeated dosing, accumulate and put patients at …

Former studies have revealed intersex variability in immune response to infectious diseases,
including Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory …

Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis.
Both disease entities are correlated with increased incidence of venous thrombotic events …

Heparin, being a widely employed anticoagulant in numerus clinical complications, requires
strict quantification and qualitative screening to ensure the safety of patients from potential …

Heparin-induced thrombocytopenia (HIT), a severe autoimmune disorder, occurs in patients
undergoing heparin therapy. The presence of platelet-activating antibodies against platelet …

Historically, treatment of heparin-induced thrombocytopenia (HIT) includes a non-heparin
parenteral anticoagulant with bridging to warfarin once platelets recover. Data supporting …